Ponatinib for Squamous Cell Lung and Head and Neck Cancers
This study has been terminated.
(FDA hold and toxicity associated with study drug)
Dana-Farber Cancer Institute
First Posted: January 7, 2013
Last Update Posted: December 23, 2014
Information provided by (Responsible Party):
Peter S. Hammerman, Dana-Farber Cancer Institute